---

Highlights of Deals in November– 2025

 

Acquisitions:

1.     Cipla to acquire Inzpera Healthsciences for US$12.27 Million.

2.     Solventum to acquire Acera Surgical in US$725 Million deal.

3.     Investment firm HSG to buy Bayer’s Avelox antibiotics business.

4.     Gilead acquires Sprint’s TREX1 immunotherapy programme for US$400 Million. This deal will see Gilead pay over US$14 Million upfront for the three-prime repair exonuclease 1 (TREX1) blocker.

Licensing:

1.     AstraZeneca India and Sun Pharma announced a second brand partnership for sodium zirconium cyclosilicate (SZC) in India. SZC is an innovative and highly effective treatment for hyperkalaemia.

2.     Zydus and SIG sign deal for novel packaging solution to unveil first single-serve spouted pouches for liquid cough and cold medication.

3.     Mankind Pharma inks licencing pact with Actimed to bring cachexia treatments to India and South Asian Territories.

4.     Zydus has signed an exclusive licensing and commercialisation agreement with US-based RK Pharma Inc. The agreement is for a novel sterile injectable 505(b)(2) oncology supportive care product for the US market.

5.     Novo Nordisk India partners with Emcure to commercialise Poviztra in India.

6.     Roche inks US$200 Million plus licensing pact for Freenome's cancer screening blood tests.

7.     Evonik and InVitria form strategic partnership to supply animal-free albumin to global biopharma market.

8.     Chiesi inks agreement with AbbVie subsidiary to push next-generation brain-targeting therapies for rare diseases.

9.     Adagene inks licensing deal with Third Arc Bio.

10.  EirGenix inks licensing agreement with Sandoz AG for commercialization of its independently developed breast cancer biosimilar, EG1206A.

 

Investments:

1.     Natco Pharma has acquired a 35.75% stake in Adcock Ingram Holdings, a South African pharmaceutical company, for approximately US$226 Million.

2.     Omron Healthcare announces second investment in Tricog Health to advance AI-powered cardiac care in India.

3.     AstraZeneca invests additional US$136 Million to expand Qingdao inhalants facility.

 

 

Aagami Updates:

1.     Aagami Secures Contract Extension from US Client to Develop Phase 3 EPO Asset for Sudden Cardiac Arrest Resuscitation.

2.     Japanese client with FDA approved lidocaine patch has awarded contract extension to Aagami.

3.     Bio-Europe 2025 Wrap-Up: Aagami successfully concluded its participation in Bio-Europe (November 3–5, 2025), with 30+ one-on-one strategic meetings with key industry decision-makers.

4.     Aagami is also all set to participate in JP Morgan Healthcare Week and BIOTECH SHOWCASE | Jan 12-14, 2026 | San Francisco. Meeting calendar is open now.

 

Select opportunities available with us:

For Partnering/Licensing/ Co-development:

1. Seeking Licensing / Distribution Partners: Marketed Povidone-Iodine Nasal Spray (Nasodine®), patented, clinically proven to eliminate respiratory viruses and bacteria, offering safe and effective relief from cold, flu, and nasal congestion. Commercially launched in Singapore (2024) as an antiseptic liquid, with all government hospitals adoption and strong retail traction; Offering an attractive ready-to-launch OTC opportunity in multiple markets(except Singapore, Brunei, Malaysia and the Philippines where already partnered).

2.     US Licensing: FDA Approved Patented Lidocaine Patch using proprietary technology.

3.     Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach).  By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.

4.     Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients under 72 years of age).

5. Seeking Out-licensing and Investment: Uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. Lead asset (Phase 2) and platform, both available for licensing.

6.     Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.

7.     Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit-making product. Licensing available.

 

For Acquisition:

1.    A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.

2.    Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.

3.    Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc. - for Next-generation biologics.

For Investment:

1.     High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US$90 million raised in current round, our client is offering special terms to invest. Expected ROI is 2-4x in 12-18 months via an IPO, strategic M&A, or private equity buyout.

2. Seeking Investment: Revolutionizing oncology with patented smart drug delivery platform that enhances chemotherapy efficacy while minimizing toxic side effects. Backed by US$14 million in funding and a team with 7 prior drug launches, client is advancing a pipeline of 5 chemotherapies toward IND. Targeting a US$180 billion+ oncology market.

Hope you found the content useful. We welcome your feedback and queries.